OBJECTIVE： To observe therapeutic efficacy and safety of Shensong yangxin capsules in the treatment of brainsten hemorrhage complicated with cerebrocardiac syndrome （CCS） accompanied by arrhythmia. METHODS： Medical information of 98 patients with brainstem hemorrhage complicated with CCS arrhythmia were analyzed retrospectively and divided into control group （49 cases） and observation group （49 cases） according to drug use. Control group was given routine treatment as mannitol and piracetam. Observation group was additionally given Shensong yangxin capsules 1.2 g orally or via nasal feeding， 3 times a day， on the basis of control group. Treatment course of 2 groups lasted for 4 weeks. Clinical efficacies of 2 groups were observed as well as the levels of catecholamine [norepinephrine （NE）， epinephrine （E）， dopamine （DA）]， ET-1 and NO， the occurrence of ADR before and after treatment. RESULTS： Total response rate of observation group was significantly higher than that of control group（75.5％ vs. 46.93％）， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the levels of NE， E，DA，ET-1 and NO between 2 groups（P＞0.05）. 3 and 7 d after treatment， the levels of NE， E， DA， ET-1 and NO in 2 groups were significantly lower than before， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： Based on routine treatment， Shensong yangxin capsules shows significant therapeutic efficacy for CCS， can reduce levels of catecholamine and doesn’t increase the occurrence of ADR.